• OPTI 2020 in Munich

    Visit ESW Vision at the OPTI 2020 in Munich / Germany. From January 10.-12. you can find us at booth # C6.227 - more

  • APAO 2020 in China

    Visit ESW Vision at the APAO 2020 in Xiamen / China. From April 22-26 2020 - more

  • SILMO 2019 Paris

    Visit ESW Vision at the SILMO Paris exhibition 2019. From September 27-30 you can find us at booth #5L002 - more

  • AAO 2019 San Francisco

    Visit ESW Vision at the AAO 2019 in San Francisco. From October 12 - 15 you can find us at our booth #7626 - more

  • ESCRS 2019 Paris

    Visit ESW Vision at the ESCRS Paris exhibition 2019. From September 14-17 you can find us at booth #C109 - more

  • PAAO 2019 CANCUN

     ESW Vision will be present at PAAO Congress in Cancun! Booth #2522 - more

  • APAO Bangkok 2019

    This year´s APAO  - Asia-Pacific Ophthalmology Congress will be held in Bangkok, Thailand. ESW Vision will be present on booth #Z30 - more!  
  • Visit us on booth #826 - AAO 2018

      We will be exhibiting from October 27-30 in Chicago at AAO Annual Meeting. We await you at booth #826 - more. 
  • Visit us at Optrafair

    Visit us at Optrafair 2018 in Birmingham - More
  • Save the date ESCRS Vienna 2018

    Visit us at ESCRS in Vienna - More
  • Visit us at APAO

    Feb 8-11 2018 in Hong Kong - More
  • Visit us at AAO

    AAO Meeting 2017 For the first time - meet us: Booth 4656 - More

E-Eye : Long lasting solution for dry eye management using patented IRPL® technology

E-Eye is the first medical device in the world using IRPL® (Intense Regulated Pulsed Light) that has been specifically designed for the treatment of dry eye due to Meibomian glands dysfunction (MGD).

About the dry eye syndrome due to Meibomian Gland Dysfunction (MGD)

“The Meibomian gland dysfunction has been identified as the principal cause of dry eye syndrome throughout the world”.

These are the results of the first report about Meibomian Gland Dysfonction (MGD) from the ARVO (the Association for Research in Vision and Ophthalmology) conference organized in 2010. More than 50 members and some of the biggest experts in research and Ophthalmology from around the world gathered for this event.

Dry eye syndrome is generally due to a Meibomian gland dysfunction, also called Blepharitis. This results in the important oil layer of our tears being unstable and thinner than it normally should  be, causing an insufficient production of tears, or excessive evaporation. It is now acknowledged that the majority of evaporative cases are primarily due to the lack or insufficiency of the external lipid layer of the lacrimal film, produced by the Meibomian glands.

There are approximately 80 Meibomian glands located in the upper and lower eyelids of each eye. These glands produce an oil called the lipid layer, avoiding tear evaporation and adapting tears to the irregularities of the eye surface. Lipids are made of polarized fatty acids. Their fluidity is ensured by the body temperature. They are non-polarised on the surface, giving stability to the lacrymal fluid and allowing the lubrication of the palpebral conjunctival plan. The contraction of the Riolan muscle allows the lacrymal film to spread out.

Target, symptoms & causes


Dry eye Syndrome (DES) (Dry Eye Disease, DED) is a common pathology affecting up to 30% of certain adult population groups depending on the region and 40% of people wearing contact lenses or glasses. It is recognised that a large majority of dry eye cases is caused by Meibomian Glands Dysfunction (MGD).


Affecting seniors with a greater prevalance. Females are more affected than males and a growing number of young people. Two new risk groups are emerging rapidly, “Office Dry Eye” and “Children Dry Eye”. Both due to extensive use of computer screens and electronic media.


Mainly caused by the conditions of modern life. Intensive use of screens (smart phone and computer)/ pollution / artificial lights, driving cars / windy, hot or dry weather conditions and air-conditioned rooms / contact lenses / hormonal changes / dedications / laser eye surgeries

Existing treatments and patients behavior

Due to a lack of preventive treatments, patients are waiting for their symptoms to become serious before visiting an eyecare specialist. Unfortunately, at that stage, existing solutions are often inadequate providing only temporary relief.

Short-term relief: eye drop

Available treatments mainly involve artificial eye drops. In addition, those are often stringent and insufficient to overcome the discomfort felt by patients.

Long-term relief: E-Eye IRPL®

Since 2014, a new non invasive treatment using IRPL® (Intense Regulated Pulsed Light) technology is available. E-Eye, developed and manufactured in France, is quick, gentle and offers long-lasting relief to dry eye sufferers.


  • Dryness
  • Foreign body sensation
  • Secretion
  • Burning
  • Redness
  • Fatigue
  • Blurred vision
  • Blinking
  • Itchy, scratchy eyes

Dry eye syndrome can be very annoying and prevention is the best way to avoid being afflicted by this disease.

(if the disorder is not treated)

  • Increase in vision disorders.
  • Feeling of “eye burning” stopping any visual work.
  • Permanent discomfort.
  • Paradoxal tear increase.
  • Inability to wear contact lenses.
  • Anatomical modifications.
  • Atrophy of the meibomian glands orifices.
  • Episodical infections, sties, conjunctival secondary infections, chalazion.
  • Apparition of micro-ulcerations of the epithelium cornea.

How does it work?

E-Eye does not directly affect the Meibomian glands. Its action is indirect. The “flashed” areas (buborbital and zygomatic region) are the areas where the parasympathetic nerve passes.

It has been proven in several neurological studies that the emission on a nerve of infrared as a train of pulses leads to the creation of a micro gradient of temperature between the inner and the outer layer of the myelin sheath.

This micro gradient of temperature triggers the liberation of neurotransmitters. Automatically, the parasympatic nerve is connected to the Meibomian glands by some of its branches. The neurotransmitters released will then be able to interact with the glands, stimulating the secretion and the contraction of the latter.

As a result the dry lipid layer will have a natural flow of lipid and the tears evaporation will be reduced, preventing the eyes to get dry. The Meibomian glands will return to their normal functions.

The latest IRPL® technology

E-Eye is a medical device that has been specifically designed for treating dry eye syndrome due to MGD.

It generates an Intense Regulated Pulsed Light by producing perfectly calibrated and homogeneously sequenced light pulses. The sculpted pulses are delivered under the shape of train pulses. The energy, spectrum and time period are precisely set to stimulate the Meibomian glands in order for them to return their normal function. E-Eye is a tool for treating and preventing dry eyes.

Made in France

100% developed and made in France by E-Swin, the world largest IPL device manufacturer.

E-Swin  has an ISO 13485 certification for the design and manufacturing of medical devices.

Our certifications

E-Swin has been an ISO 13485 certified company since 2008.

Every device we sell carries the European “CE” marking, which belongs to the “medical devices” category.

Manufacturing a product in line with the requirements of ISO 13485  allows for full traceability, not only of all of our devices sold but also of all of their components. Quality control of each of the components of our devices carrying the medical certification is carried out during the manufacture of each component at the time of delivery of these components and via numerous tests following their integration into the final device.

E-Eye Worldwide

Since the start of international distribution in 2016, E-Eye has set up in many countries. E-Eye is a proven solution now available in more than 50 countries around the world !More than 300.000 sessions were already done, on 100.000 satisfied clients worldwide.

Key Figures

  • No. 1 dry eye solution to treat Meibomian Gland Dysfunction (MGD).
  • In 2018, over 100.000 patients have been treated with the E-Eye worldwide!
  • + 85% satisfaction rate, proven efficacy on mild, medium and severe dry eye.
  • Several clinical studies conducted with highly significant results.
  • Up to 3 years longterm relief for your patient.